Category: Pharma, Life Sciences & Med Tech Players
-
Moderna and GlaxoSmithKline settle mRNA vaccine dispute with cross-license; “not obligated to make payments”
The agreement settles pending litigation in the United States and Europe.
-
$9M attorney fees award reversed by Federal Circuit for Myriad-plus proof of unpatentability
The panel concluded that while the plaintiff “ultimately did not prevail, it cannot be said that the substantive strength of its… position was so exceptionally meritless” as to justify the fees award.
-
Pfizer fends off Paxlovid patent suit: UPC Munich LD invalidates patent; EPO Opposition Division also leaning toward invalidation
Pfizer is in a strong position against Enanta in a Paxlovid-related patent case as the plaintiff will need to overcome both a UPC first-instance decision and an EPO preliminary opinion.
-
UPC Hague LD grants Caelus gut bacterium PI against rivals, then backtracks: overbroad requests ‘should not be rewarded’
The UPC’s Hague Local Division granted Caelus a preliminary injunction over a gut bacterium patent, then trimmed a website notice order after concluding the wording reached further than was originally intended.
-
China’s top court clarifies when claim amendments can end drug patent-linkage cases: how U.S. Hatch-Waxman actions differ
Narrowing claims can save a drug patent but end its pending linkage case in China. A newly posted Supreme People’s Court case explains when that can happen, while U.S. Hatch-Waxman cases illustrate different requirements for litigating amended claims before launch.
-
UPC’s CD Milan assumes jurisdiction over declaratory judgment concerning future divisionals and over anti-abandonment injunctions
The UPC’s CD Milan has taken an expansive stance on declaratory and injunctive relief for the purpose of thwarting the so-called divisional game, but has also recognized the need for appellate guidance.
-
University of Washington DNA sequencing patent at center of $245M damages award survives second PTAB run
Guardant Health petitioned for IPR of the patent in response to a district court infringement complaint brought by the university and TwinStrand Biosciences.
-
EPO Board of Appeal revokes Novo Nordisk’s cardiovascular semaglutide patent; generics could enter EU as early as 2031
The Board found the claims lacked priority, so a clinical study publication destroyed novelty, leaving Ozempic and Wegovy potentially vulnerable to competition earlier than expected.
-
Halozyme wins Dutch injunction against Merck’s Keytruda SC in eight European countries, court holds patent valid
The Hague District Court has upheld Halozyme’s patent and found infringement. Merck’s subcutaneous cancer drug is blocked in eight European countries, but Merck strongly disagrees, alleging the patent is invalid.
-
Janssen wins landmark preliminary injunction in District of Delaware
The U.S. District Court has issued a preliminary injunction against Accord BioPharma and Bio- Thera Solutions over the alleged infringement of 17 of Janssen’s patents related to golimumab, a key ingredient in its drugs used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.